91 112

Cited 0 times in

경증 및 중등도 본태성 고혈압 환자에서 Telmisartan (Micardis® )의 강압효과 및 임상적 안전성에 대한 연구

Other Titles
 Clinical Study on Anti-Hypertensive Effect and Safety of Telmisartan (Micardis®) in Mild to Moderate Hypertensive Patients 
 윤영원  ;  이병권  ;  변기현  ;  강석민  ;  안신기  ;  최동훈  ;  하종원  ;  장양수  ;  정남식  ;  심원흠  ;  조승연  ;  김성순 
 Korean Circulation Journal (순환기), Vol.30(10) : 1264-1270, 2000 
Journal Title
 Korean Circulation Journal (순환기) 
Issue Date
Telmisartan, Hypertension, Angiotensin II receptor blocker
Background and Objectives:Telmisartan (Micardis®), a selective type Ⅰ angiotensin Ⅱ receptor blocker, has recently been introduced as a new antihypertensive agent. We evaluated its anti-hypertensive effect and safety in mild to moderate hypertensive patients. Materials and Methods:Telmisartan, 40 mg, was started once a day over the 4 week period in 45 patients with mild to moderate hypertension (35 male, mean age:54. 9±8.7 years). The dose was maintained in the patients whose blood pressures were controlled below 140/90 mmHg for the following 4 weeks. In those patients whose blood pressures did not fall below 140/90 mmHg, the dose was doubled to 80 mg per day for the following 4 weeks. Blood pressures were assessed at the 8th week of administration. For safety evaluation, laboratory tests were performed before and after treatment with telmisartan. Changes in heart rate and electrocardiogram were also observed. Results:1) The mean blood pressures in the sitting position were 161.6±14.7 mmHg (systolic) and 102.4±4.3 mmHg (diastolic) before treatment, which were lowered to 139.5±15.8 mmHg and 90.2±8.0 mmHg repectively after 8 weeks of treatment (p<0.05). 2) Heart rate was not significantly changed after treatment with telmisartan compared to pre-treatment (72.5±7.2/min vs. 71.7±7.5/min;p>0.05). 3) Laboratory tests revealed no significant abnormality by the treatment with telmisartan. 4) No significant side effects were observed during the treatment period. Conclusion:Telmisartan, 40 mg or 80 mg, once a day induced significant reduction in systolic and diastolic blood pressures without significant side effects in the patients with mild to moderate hypertension. Telmisartan is thought to be a well tolerated and effective antihypertensive agent. (Korean Circulation J 2000;30(10):1264-1270)
Files in This Item:
T200003636.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Min(강석민) ORCID logo https://orcid.org/0000-0001-9856-9227
Ahn, Shin Ki(안신기) ORCID logo https://orcid.org/0000-0002-9822-7961
Jang, Yang Soo(장양수) ORCID logo https://orcid.org/0000-0002-2169-3112
Chung, Nam Sik(정남식)
Choi, Dong Hoon(최동훈) ORCID logo https://orcid.org/0000-0002-2009-9760
Ha, Jong Won(하종원) ORCID logo https://orcid.org/0000-0002-8260-2958
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.